Israel’s NeoTX uses Selective T cell Redirection (STR) technology to enlist a powerful immune response against tumors. Mutated bacteria are fused with monoclonal antibodies which target the tumor’s 5T4 antigen, alerting T-cells to kill the tumor. NeoTX has just raised $45 million of funds.
https://www.calcalistech.com/ctech/articles/0,7340,L-3794957,00.html